These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 32706102)

  • 21. Real-world use of osimertinib in non-small cell lung cancer: ASTRIS study Korean subgroup analysis.
    Cho BC; Kim DW; Park K; Lee JS; Yoo SS; Kang JH; Lee SY; Kim CH; Jang SH; Kim YC; Yoon HK; Han JY; Kim SW
    Curr Med Res Opin; 2020 Mar; 36(3):477-482. PubMed ID: 31581843
    [No Abstract]   [Full Text] [Related]  

  • 22. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
    Nakao A; Hiranuma O; Uchino J; Sakaguchi C; Kita T; Hiraoka N; Ishizuka T; Kubota Y; Kawasaki M; Goto Y; Imai H; Hattori N; Nakatomi K; Uramoto H; Uryu K; Fukuda M; Uchida Y; Yokoyama T; Akai M; Mio T; Nagashima S; Chihara Y; Tamiya N; Kaneko Y; Mouri T; Yamada T; Yoshimura K; Fujita M; Takayama K
    Oncologist; 2019 May; 24(5):593-e170. PubMed ID: 30651400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
    Xing L; Pan Y; Shi Y; Shu Y; Feng J; Li W; Cao L; Wang L; Gu W; Song Y; Xing P; Liu Y; Gao W; Cui J; Hu N; Li R; Bao H; Shao Y; Yu J
    Clin Cancer Res; 2020 Dec; 26(23):6168-6175. PubMed ID: 32817079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
    Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
    Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
    J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
    Lee K; Kim D; Yoon S; Lee DH; Kim SW
    Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.
    Mu Y; Hao X; Yang K; Ma D; Wang S; Xu Z; Li J; Xing P
    Target Oncol; 2019 Jun; 14(3):335-342. PubMed ID: 31124059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with unknown T790M mutation: a case report and review of literature.
    Hachlaf M; Lkhoyaali S; Nadir W; Lemsyeh H; El Ghissassi B; Mrabti H; Boutayeb S; Errihani H
    J Med Case Rep; 2024 Aug; 18(1):374. PubMed ID: 39113087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
    Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
    Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.
    Cortellini A; Leonetti A; Catino A; Pizzutillo P; Ricciuti B; De Giglio A; Chiari R; Bordi P; Santini D; Giusti R; De Tursi M; Brocco D; Zoratto F; Rastelli F; Citarella F; Russano M; Filetti M; Marchetti P; Berardi R; Torniai M; Cortinovis D; Sala E; Maggioni C; Follador A; Macerelli M; Nigro O; Tuzi A; Iacono D; Migliorino MR; Banna G; Porzio G; Cannita K; Ferrara MG; Bria E; Galetta D; Ficorella C; Tiseo M
    Clin Transl Oncol; 2020 Jun; 22(6):844-851. PubMed ID: 31392645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.
    Yang Z; Yang J; Chen Y; Shao YW; Wang X
    Target Oncol; 2019 Aug; 14(4):369-374. PubMed ID: 31301016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies.
    Ahn MJ; Tsai CM; Shepherd FA; Bazhenova L; Sequist LV; Hida T; Yang JCH; Ramalingam SS; Mitsudomi T; Jänne PA; Mann H; Cantarini M; Goss G
    Cancer; 2019 Mar; 125(6):892-901. PubMed ID: 30512189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment.
    Yang Y; Liu Q; Cao L; Sun W; Gu X; Liu B; Xiao N; Teng F; Li X; Chen M; Yu W; Lin H; Xu G
    BMC Pulm Med; 2021 May; 21(1):172. PubMed ID: 34011336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.
    Schmid S; Klingbiel D; Aeppli S; Britschgi C; Gautschi O; Pless M; Rothschild S; Wannesson L; Janthur W; Foerbs D; Demmer I; Jochum W; Früh M
    Lung Cancer; 2019 Apr; 130():149-155. PubMed ID: 30885336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.
    Peng X; Long X; Liu L; Zeng L; Yang H; Jiang W; Liao D; Li K; Wang J; Lizaso A; Mao X; Xu Q; Mansfield AS; Yang N; Zhang Y
    Eur J Cancer; 2020 Dec; 141():199-208. PubMed ID: 33171317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer.
    Ichihara E; Hotta K; Ninomiya K; Kubo T; Ohashi K; Rai K; Tanaka H; Tabata M; Maeda Y; Kiura K
    Lung Cancer; 2019 Jun; 132():54-58. PubMed ID: 31097094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
    Popat S; Jung HA; Lee SY; Hochmair MJ; Lee SH; Escriu C; Lee MK; Migliorino MR; Lee YC; Girard N; Daoud H; Märten A; Miura S
    Lung Cancer; 2021 Dec; 162():9-15. PubMed ID: 34649106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.